Gibson Christopher 4
4 · RECURSION PHARMACEUTICALS, INC. · Filed Mar 11, 2026
Research Summary
AI-generated summary of this filing
Recursion (RXRX) Director Christopher Gibson Converts and Gifts 20,000 Shares
What Happened
Christopher Gibson, a director of Recursion Pharmaceuticals (RXRX), reported three related transactions on March 9, 2026: two conversions of derivative securities (each for 20,000 shares) and a gift of 20,000 shares. The conversions and the gift were reported at $0 per share (conversion/gift, not an open‑market trade). One conversion is listed as an acquisition of 20,000 shares and the other conversion and the gift are recorded as dispositions.
Key Details
- Transaction date: 2026-03-09; Form 4 filed 2026-03-11 (appears timely).
- Transactions recorded at $0.00 per share (conversion/gift), not a market purchase/sale.
- Reported items: Conversion of derivative security — 20,000 shares (acquired); Gift — 20,000 shares (disposed); Conversion of derivative security — 20,000 shares (disposed; derivative).
- Shares owned after the transactions: not specified in the filing.
- Relevant footnote: F1 — Class B common stock is convertible into Class A common stock at the holder’s option and has no expiration date.
- No cash proceeds were reported (gift and conversion).
Context
Conversions of Class B shares into Class A (recorded at $0) reflect a change in share class/ownership form rather than a purchase. Gifts are transfers that do not indicate a buy/sell market view and produce no cash to the insider. This filing reports conversion/gift activity by a director and is informational for shareholders tracking insider movements.
Insider Transaction Report
- Conversion
Class A Common Stock
[F1][F2]2026-03-09+20,000→ 926,556 total - Gift
Class A Common Stock
[F2]2026-03-09−20,000→ 906,556 total - Conversion
Class B Common Stock
[F1]2026-03-09−20,000→ 4,523,334 totalExercise: $0.00→ Class A Common Stock (20,000 underlying)
- 386,000(indirect: By LLC)
Class B Common Stock
[F1][F3]Exercise: $0.00→ Class A Common Stock (0 underlying) - 388,000(indirect: By LLC)
Class B Common Stock
[F1][F4]Exercise: $0.00→ Class A Common Stock (0 underlying) - 50,000(indirect: By Trust)
Class B Common Stock
[F1][F5]Exercise: $0.00→ Class A Common Stock (0 underlying) - 1,050,567
Stock Option (Right to Buy)
[F6]Exercise: $7.25Exp: 2035-02-03→ Class A Common Stock (0 underlying) - 666,898
Stock Option (Right to Buy)
[F7]Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying) - 813,600
Stock Option (Right to Buy)
[F8]Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying) - 399,002
Stock Option (Right to Buy)
[F9]Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 5,436
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 282,500
Stock Option (Right to Buy)
[F10]Exercise: $2.48Exp: 2030-12-30→ Class A Common Stock (0 underlying)
Footnotes (10)
- [F1]Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
- [F10]The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F2]This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
- [F3]The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
- [F4]The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
- [F5]The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
- [F6]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F7]The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
- [F9]The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.